Skip to main content

Table 6 The Cox regression model of the main adverse events

From: The safety of antithrombotic therapy in patients with cerebral microbleeds and cardiogenic cerebral embolism due to nonvalvular atrial fibrillation

Variable

All-cause death

CH events

Hazard Ratio

95% confidence interval

P value

Hazard Ratio

95% confidence interval

P value

CMBs

1.467

0.532–4.044

0.458

2.349

0.945–5.840

0.066

Male gender

0.714

0.263–1.944

0.510

0.854

0.331–2.206

0.745

Smoking

1.613

1.117–2.328

0.036

1.413

0.951–2.102

0.090

Hypertension history

1.769

0.538–5.814

0.347

2.840

1.886–4.276

0.025

Diabetes history

1.252

0.453–3.459

0.665

1.251

0.470–3.327

0.654

CI history

1.819

0.615–5.380

0.279

0.633

0.174–2.301

0.488

CH history

4.178

2.336–7.472

0.026

3.028

1.524–6.017

0.038

Anticoagulant therapy

0.690

0.573–0.832

0.003

1.724

0.664–4.772

0.263

NIHSS score ≥ 5

1.613

1.372–1.896

< 0.001

2.376

1.236–4.569

0.043

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us